This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
It is no longer the current profile. Read the canonical profile and its correction notice.
Update · July 29, 2026
We added FDA substance-identity aliases to improve search matching. The cited compounding-list status did not change. 2
What this version reported
FDA lists GHK-Cu, except injectable routes, in Category 1 for bulk substances under evaluation. That listing does not establish FDA approval, safety, or effectiveness.↗
Organizations named in cited records:
- U.S. Food and Drug Administration↗
Sources for this version
- 1503A bulk drug substances under evaluation · GHK-Cu except injectable routes · updated May 14, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked July 22, 2026
- 2Copper tripeptide-1 substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked July 29, 2026